{
    "id": "e77efbf4-6a82-42ba-aea3-f833b599dcdc",
    "indications": "prempro/premphase estrogen plus progestin indicated woman uterus : • treatment moderate severe vasomotor symptoms due menopause ( 1.1 ) • treatment moderate severe vulvar vaginal atrophy due menopause ( 1.2 ) • prevention postmenopausal osteoporosis ( 1.3 )",
    "contraindications": "estrogen-alone , combination progestin , lowest effective dose shortest duration consistent treatment goals risks individual woman . postmenopausal women re-evaluated periodically clinically appropriate determine treatment still necessary .",
    "warningsAndPrecautions": "prempro therapy consists single tablet taken daily . prempro 0.3 mg/1.5 mg ndc 0046-1105-11 , carton includes 1 blister card containing 28 oval , cream tablets . prempro 0.45 mg/1.5 mg ndc 0046-1106-11 , carton includes 1 blister card containing 28 oval , gold tablets . prempro 0.625 mg/2.5 mg ndc 0046-1107-11 , carton includes 1 blister card containing 28 oval , peach tablets . prempro 0.625 mg/5 mg ndc 0046-1108-11 , carton includes 1 blister card containing 28 oval , light-blue tablets . premphase therapy consists two separate tablets ; one maroon premarin tablet taken daily days 1 14 one light-blue tablet taken days 15 28. ndc 0046-2575-12 , carton includes 1 blister card containing 28 tablets ( 14 oval , maroon premarin tablets 14 oval , light-blue tablets ) . appearance prempro tablets trademark pfizer inc. appearance premarin tablets trademark pfizer inc. appearance conjugated estrogens/medroxyprogesterone acetate combination tablets trademark .",
    "adverseReactions": "prempro premphase contraindicated women following conditions : •undiagnosed abnormal genital bleeding [ ( 5.2 ) ] •breast cancer history breast cancer [ ( 5.2 ) ] •estrogen-dependent neoplasia [ ( 5.2 ) ] •active dvt , pe , history conditions [ ( 5.1 ) ] •active arterial thromboembolic disease ( example , stroke myocardial infarction ) , history conditions [ ( 5.1 ) ] •known anaphylactic reaction angioedema prempro/premphase [ ( 5.15 , 5.16 ) ] •hepatic impairment disease [ ( 5.10 ) ] •protein c , protein , antithrombin deficiency , known thrombophilic disorders",
    "ingredients": [
        {
            "name": "ESTROGENS, CONJUGATED",
            "code": "IU5QR144QX"
        },
        {
            "name": "MEDROXYPROGESTERONE ACETATE",
            "code": "C2QI4IOI2G"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "TRIBASIC CALCIUM PHOSPHATE",
            "code": "91D9GV0Z28"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "HYPROMELLOSE 2208 (15000 MPA.S)",
            "code": "Z78RG6M2N2"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        }
    ],
    "organization": "Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",
    "name": [
        {
            "name": "Premphase"
        },
        {
            "name": "Prempro"
        }
    ],
    "effectiveTime": "20250506",
    "indications_original": "PREMPRO/PREMPHASE is an estrogen plus progestin indicated in a woman with a uterus for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Prevention of Postmenopausal Osteoporosis ( 1.3 )",
    "contraindications_original": "Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.",
    "warningsAndPrecautions_original": "PREMPRO therapy consists of a single tablet to be taken once daily. \n                        \n                           PREMPRO 0.3 mg/1.5 mg\n                        \n                        NDC 0046-1105-11, carton includes 1 blister card containing 28 oval, cream tablets.\n                        \n                           PREMPRO 0.45 mg/1.5 mg\n                        \n                        NDC 0046-1106-11, carton includes 1 blister card containing 28 oval, gold tablets.\n                        \n                           PREMPRO 0.625 mg/2.5 mg\n                        \n                        NDC 0046-1107-11, carton includes 1 blister card containing 28 oval, peach tablets.\n                        \n                           PREMPRO 0.625 mg/5 mg\n                        \n                        NDC 0046-1108-11, carton includes 1 blister card containing 28 oval, light-blue tablets.\n                        \n                           PREMPHASE therapy consists of two separate tablets; one maroon Premarin tablet taken daily on days 1 through 14 and one light-blue tablet taken on days 15 through 28.\n                        NDC 0046-2575-12, carton includes 1 blister card containing 28 tablets (14 oval, maroon Premarin tablets and 14 oval, light-blue tablets).\n                        The appearance of PREMPRO tablets is a trademark of Pfizer Inc.\n                        The appearance of PREMARIN tablets is a trademark of Pfizer Inc. The appearance of the conjugated estrogens/medroxyprogesterone acetate combination tablets is a trademark.",
    "adverseReactions_original": "PREMPRO and PREMPHASE are contraindicated in women with any of the following conditions:\n                  \n                     \n                        •Undiagnosed abnormal genital bleeding [see Warnings and Precautions (5.2)]\n                     \n                     \n                        •Breast cancer or a history of breast cancer [see Warnings and Precautions (5.2)]\n                     \n                     \n                        •Estrogen-dependent neoplasia [see Warnings and Precautions (5.2)]\n                     \n                     \n                        •Active DVT, PE, or a history of these conditions [see Warnings and Precautions (5.1)]\n                     \n                     \n                        •Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions [see Warnings and Precautions (5.1)]\n                     \n                     \n                        •Known anaphylactic reaction or angioedema with PREMPRO/PREMPHASE [see Warnings and Precautions (5.15, 5.16)]\n                     \n                     \n                        •Hepatic impairment or disease [see Warnings and Precautions (5.10)]\n                     \n                     \n                        •Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders"
}